Search results for "Clinical-trial"

showing 10 items of 19 documents

Effect of acetyl-l-carnitine in the treatment of diabetic peripheral neuropathy : A systematic review and meta-analysis

2017

Background/aim: Deficiency of acetyl-L-carnitine (ALC) and L-carnitine (LC) appears to play a role in peripheral diabetic neuropathy, although the evidence in humans is still limited. We conducted a systematic review and meta-analysis investigating the effect of ALC on pain and electromyographic parameters in people with diabetic neuropathy. Methods: A literature search in major databases, without language restriction, was undertaken. Eligible studies were randomized controlled trials (RCTs) or pre-and post-test studies. The effect of ALC supplementation on pain perception and electromyographic parameters in patients with diabetic neuropathy was compared vs. a control group (RCTs). The effe…

medicine.medical_specialtyDiabetic neuropathyDiabetePlaceboNerve conduction velocitylaw.inventionRATS03 medical and health sciencesGLUTAMATE0302 clinical medicineRandomized controlled triallawDiabetes mellitusMedicineQUALITYMeta-analysi030212 general & internal medicineUlnar nerveAdverse effectbusiness.industryDiabetesNERVE GROWTH-FACTORPAINmedicine.diseaseAcetyl-L-carnitine3. Good healthSurgeryNeuropathyAcetyl-L-carnitine; Diabetes; Meta-analysis; Neuropathy; Gerontology; Geriatrics and GerontologyMeta-analysisPeripheral neuropathyAnesthesia3121 General medicine internal medicine and other clinical medicineGeriatrics and GerontologybusinessGerontology030217 neurology & neurosurgeryCLINICAL-TRIALS
researchProduct

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial

2015

KRAS mutation has been reported as a marker of radio-resistance in rectal cancer and unfavourable outcome in both colon and rectal cancer. This study suggests that a single-nucleotide polymorphism of the KRAS gene (LCS-6 variant) may predict response to neoadjuvant treatment and mitigate the poor prognosis associated with KRAS mutation in locally advanced rectal cancer.

MaleOncologyOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLET-7 MICRORNA-BINDINGCetuximabmedicine.disease_causeCOLORECTAL-CANCER3'-UNTRANSLATED REGION0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsRectal cancerNeoadjuvant therapySingle-nucleotide polymorphism0303 health sciencesCetuximabCOLON-CANCERHazard ratioCAPOX RegimenChemoradiotherapyHematologysingle-nucleotide polymorphismMiddle AgedCombined Modality TherapyNeoadjuvant TherapyBINDING SITE POLYMORPHISM3. Good healthOxaliplatinLet-7Oncology030220 oncology & carcinogenesis5-FLUOROURACIL/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleKRASLife Sciences & Biomedicinemedicine.drugAdultGenetic Markersmedicine.medical_specialtyGenotypeLCS-6 KRAS variantPolymorphism Single NucleotideDisease-Free SurvivalCLINICAL-TRIALProto-Oncogene Proteins p21(ras)03 medical and health sciencesSDG 3 - Good Health and Well-beinglet-7Internal medicineGastrointestinal TumorsBiomarkers TumorKRASmedicineHumansOncology & CarcinogenesisProgression-free survivalrectal cancerneoplasmsCapecitabineAged030304 developmental biologyCancer och onkologiScience & TechnologyRectal Neoplasmsbusiness.industryOriginal Articlesmedicine.diseasedigestive system diseasesMicroRNAsCancer and Oncologybusiness1112 Oncology And CarcinogenesisChemoradiotherapyRASAnnals of Oncology
researchProduct

The impact of conversion on the risk of major complication following laparoscopic colonic surgery: an international, multicentre prospective audit.

2018

BACKGROUND: Laparoscopy has now been implemented as a standard of care for elective colonic resection around the world. During the adoption period, studies showed that conversion may be detrimental to patients, with poorer outcomes than both laparoscopic completed or planned open surgery. The primary aim of this study was to determine whether laparoscopic conversion was associated with a higher major complication rate than planned open surgery in contemporary, international practice.METHODS: Combined analysis of the European Society of Coloproctology 2017 and 2015 audits. Patients were included if they underwent elective resection of a colonic segment from the caecum to the rectosigmoid jun…

Laparoscopic surgeryMaleColorectal cancermedicine.medical_treatmentsurgery0302 clinical medicinePostoperative ComplicationsMedicineMajor complicationProspective StudiesLaparoscopySHORT-TERM OUTCOMESColectomyMedical Auditmedicine.diagnostic_testProspective auditGastroenterologyMiddle Agedlaparoscopic surgeryConversion to Open SurgeryColon cancerTreatment OutcomeElective Surgical Procedures030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleColonic surgeryAdultmedicine.medical_specialtyCLINICAL-TRIALNOOPEN COLECTOMY03 medical and health sciencesCOLORECTAL SURGERYCase mix indexgastrointestinal surgeryHumansrectal cancerRECTAL-CANCERAgedta3126business.industryElective resectionmedicine.diseaseRANDOMIZED-TRIALOPEN RESECTIONSurgeryColon cancer; gastrointestinal surgery; laparoscopic surgery; rectal cancer; surgery; GastroenterologyLaparoscopybusinessColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
researchProduct

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study …

2020

Publisher's version (útgefin grein)

MaleLife expectancyDisability-Adjusted Life YearDiseasesDiseasecommunicable diseasesystematic analysisGlobal Burden of Disease0302 clinical medicine80 and overMedicine10. No inequalityChild11 Medical and Health SciencesinjuriesAged 80 and overeducation.field_of_studySjúkdómarDEMENTIAFALLSGeneral MedicineForvarnir3. Good healthChild PreschoolHumanGBDPopulation health03 medical and health sciencesSDG 3 - Good Health and Well-beingHumansGlobal Burden of Disease StudyeducationAgedSpatial AnalysisGlobal burdenDisabilityPreventionDISABILITYInfantSpatial AnalysiMortality rateGlobal Burden of Disease Diseases Injuries Systematic analysisPREVENTIONYears of potential life lostRisk factorsDisease studyGBD; communicable disease; injuries;ITC-ISI-JOURNAL-ARTICLELife expectancyRISK-FACTORSClinical MedicineRADemographyFötlunDánartíðniÁhættuþættir030204 cardiovascular system & hematologyRisk FactorsCause of DeathGlobal health030212 general & internal medicineMortality ratePopulation health1. No povertyDisability-Adjusted Life YearsPublic Health Global Health Social Medicine and EpidemiologyMiddle Aged3142 Public health care science environmental and occupational healthAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Cause of Death; Child; Child Preschool; Disability-Adjusted Life Years; Female; Global Burden of Disease; Humans; Infant; Infant Newborn; Male; Middle Aged; Risk Factors; Spatial Analysis; Young Adult/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingLýðheilsaFemaleCLINICAL-TRIALSAdultAdolescentPopulationGlobal healthSettore MED/01 - Statistica MedicadiseasesITC-HYBRIDYoung AdultHeilbrigðisvísindiAge DistributionGeneral & Internal MedicineMortalityPreschoolDisease burdenbusiness.industryRisk FactorKlinisk medicinInfant NewbornNewborn//purl.org/pe-repo/ocde/ford#3.02.00 [https]Folkhälsovetenskap global hälsa socialmedicin och epidemiologiÁverkarSystematic analysisNAbusiness
researchProduct

Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observat…

2020

Abstract: Background The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) assesses quality of life (QOL) in patients with lung cancer and was the first EORTC module developed for use in international clinical trials. Since its publication in 1994, major treatment advances with possible effects on QOL have occurred. These changes called for an update of the module and its international psychometric validation. We aimed to investigate the scale structure and psychometric properties of the updated lung cancer module, QLQ-LC29, in patients with lung cancer. Methods This international, observational field study was done in…

Malemedicine.medical_specialtyPsychometricsPsychometrics10255 Clinic for Thoracic SurgeryQUESTIONNAIRE610 Medicine & health03 medical and health sciences0302 clinical medicineCronbach's alphaQuality of lifeCarcinoma Non-Small-Cell LungSurveys and QuestionnairesMedicine and Health SciencesmedicineHumans030212 general & internal medicineVALIDITYLung cancerAgedLanguagebusiness.industryQLQ-C30CancerMiddle Agedmedicine.diseaseSmall Cell Lung CarcinomaTRENDShumanitiesConfirmatory factor analysisClinical trialOncology030220 oncology & carcinogenesisQuality of LifePhysical therapyFemaleObservational study2730 OncologyHuman medicinebusinessCLINICAL-TRIALS
researchProduct

Exercise treatment effect modifiers in persistent low back pain: an individual participant data meta-analysis of 3514 participants from 27 randomised…

2020

BackgroundLow back pain is one of the leading causes of disability worldwide. Exercise therapy is widely recommended to treat persistent non-specific low back pain. While evidence suggests exercise is, on average, moderately effective, there remains uncertainty about which individuals might benefit the most from exercise.MethodsIn parallel with a Cochrane review update, we requested individual participant data (IPD) from high-quality randomised clinical trials of adults with our two primary outcomes of interest, pain and functional limitations, and calculated global recovery. We compiled a master data set including baseline participant characteristics, exercise and comparison characteristic…

MINIMAL INTERVENTIONMOTOR CONTROL EXERCISESMedical and Health SciencesBody Mass Index0302 clinical medicineEngineeringGRADED ACTIVITYOrthopedics and Sports MedicineMass index030212 general & internal medicineRandomized Controlled Trials as TopicGENERAL EXERCISEexercise rehabilitationPATIENT-LEVELGeneral MedicineLow back painPeer reviewExercise TherapyMeta-analysis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingmedicine.symptommedicine.medical_specialtyExercise treatmentPhysical Therapy Sports Therapy and Rehabilitationintervention effectivenessFUNCTION-CENTERED REHABILITATIONCLINICAL-TRIALEducationHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]03 medical and health sciencesRC925SDG 3 - Good Health and Well-beingmedicineHumansFLEXION-DISTRACTIONProtocol (science)business.industryIndividual participant dataChronic Low Back Pain IPD Meta-Analysis GroupECOLOGICAL BIASSYSTEMATIC REVIEWSClinical trialmeta-analysislower backPhysical therapybusinessLow Back Pain030217 neurology & neurosurgerySport Sciences
researchProduct

Health-related quality of life is a prognostic factor for survival in older patients after colorectal cancer diagnosis: A population-based study

2015

International audience; Background: Studies carried out in the context of clinical trials have shown a relationship between survival and health-related quality of life in colorectal cancer patients.Aims: We assessed the prognostic value of health-related quality of life at diagnosis and of its longitudinal evolution on survival in older colorectal cancer patients. Methods: All patients aged >= 65 years, diagnosed with new colorectal cancer between 2003 and 2005 and registered in the Digestive Cancer Registry of Burgundy were eligible. Patients were asked to complete the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 at inclusion, three, six …

MaleMultivariate analysisColorectal cancerAppetiteDefinitions0302 clinical medicineQuality of lifeSurveys and QuestionnairesCancer registries030212 general & internal medicineAged 80 and overRelative survivalHazard ratioGastroenterologyScoresPrognosis3. Good healthSurvival RateOncology030220 oncology & carcinogenesisColonic NeoplasmsFemalePerspectivesmedicine.medical_specialtyPredict survivalClinical-TrialsContext (language use)Prognostic factorsFeeding and Eating DisordersAssociation03 medical and health sciencesInternal medicinePatient report outcomemedicineHumansMortalitySurvival rateAgedHepatologyRectal Neoplasmsbusiness.industryElderly-patientsCancer[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseElderly patientsQuality of LifePhysical therapyEuropean-organizationbusinessFollow-Up StudiesDigestive and Liver Disease
researchProduct

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted …

2013

Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. Patients and Methods We conducted an open-label, multicenter, randomized trial among adult patients with previously untreated stages II to IV FL to compare efficacy of eight doses of R associated with eight cycles of cyclophosphamide, vincristine, and prednisone (CVP) or six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or six cycles of fludarabine and mitoxantrone (FM). The principal end point of the study was time to treatment failure (TTF). Results There were 534 patients…

MaleCancer ResearchLymphomamedicine.medical_treatmentFollicular lymphomaCHOPGastroenterologyAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesLymphoma FollicularNON-HODGKINS-LYMPHOMASAdult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Vincristine; Oncology; Cancer ResearchCHEMOTHERAPYMiddle AgedPrognosisChemotherapy regimenFludarabineSurvival RateOncologyVincristineFemaleFLUDARABINECLINICAL-TRIALSVidarabinemedicine.drugAdultVincristinemedicine.medical_specialtyAdult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; VincristineInternal medicinemedicineHumansRITUXIMABSurvival rateCyclophosphamideRESPONSE CRITERIAAgedNeoplasm StagingChemotherapyMitoxantronebusiness.industryFollicularmedicine.diseasePHASE-IIISurgery1ST-LINE TREATMENTDoxorubicinPrednisoneMitoxantroneNeoplasm GradingbusinessFollow-Up StudiesJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Rehabilitation of the severely atrophied dentoalveolar ridge in the aesthetic region with corticocancellous grafts from the iliac crest and dental im…

2016

Background The aim of this study was to assess changes in bone volume after block bone augmentation and placement of dental implants and further evaluate the aesthetic outcome of the treatment. Material and Methods 9 Patients with atrophied anterior maxilla were included in this study. They received total of 21 implants. Dimensions of the alveolar ridge were measured from cone-beam computed tomography x-rays. The bone level at the implant sites was analysed from intraoral x-rays and the aesthetic outcome was assessed from clinical photographs using a pink aesthetic score (PES) scaling. Results The mean gained horizontal bone width at the marginal crest and 5 mm apically was accordingly 2.7m…

DentistryIliac crest0302 clinical medicineMaxillaaesthetic regionOrthodonticsBone TransplantationDental Implantation EndosseousSoft tissueAlveolar Ridge AugmentationAlveolar Ridge Augmentation:CIENCIAS MÉDICAS [UNESCO]ANTERIOR MAXILLATreatment Outcomemedicine.anatomical_structure030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASAUGMENTATIONCONSECUTIVE PATIENTSOral Surgerysurvival ratepink aesthetic scoreEstheticsCONTROLLED CLINICAL-TRIALIlium03 medical and health sciencesRESTORATIONSmedicineAlveolar ridgeHumansRECONSTRUCTIONcorticocancellous bone graftsGeneral DentistrySurvival rateDental ImplantsSINGLE-TOOTH IMPLANTSbusiness.industrySOFT-TISSUEResearch030206 dentistry313 DentistryGUIDED BONE REGENERATIONOtorhinolaryngologyMaxillaSurgeryCrestImplantFOLLOW-UPbusinessFollow-Up StudiesMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct